Biotech startup AviadoBio emerges with $80M for neuro disorder gene therapies
AviadoBio’s gene therapies are designed to achieve widespread distribution throughout the central nervous system. The company’s lead program on track to begin human testing as a treatment for frontotemporal dementia.